» Articles » PMID: 29078749

Endocrine and Exocrine Pancreatic Insufficiency After Acute Pancreatitis: Long-term Follow-up Study

Overview
Publisher Biomed Central
Specialty Gastroenterology
Date 2017 Oct 29
PMID 29078749
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Patients could develop endocrine and exocrine pancreatic insufficiency after acute pancreatitis (AP), but the morbidity, risk factors and outcome remain unclear. The aim of the present study was to evaluate the incidence of endocrine and exocrine pancreatic insufficiency after AP and the risk factors of endocrine pancreatic insufficiency through a long-term follow-up investigation.

Methods: Follow-up assessment of the endocrine and exocrine function was conducted for the discharged patients with AP episodes. Oral Glucose Tolerance Test (OGTT) and faecal elastase-1(FE-1) test were used as primary parameters. Fasting blood-glucose (FBG), fasting insulin (FINS), glycosylated hemoglobin HBA1c, 2-h postprandial blood glucose (2hPG), Homa beta cell function index (HOMA-β), homeostasis model assessment of insulin resistance (HOMA-IR) and FE-1 were collected. Abdominal contrast-enhanced computed tomography (CECT) was performed to investigate the pancreatic morphology and the other related data during hospitalization was also collected.

Results: One hundred thirteen patients were included in this study and 34 of whom (30.1%) developed diabetes mellitus (DM), 33 (29.2%) suffered impaired glucose tolerance (IGT). Moreover, 33 patients (29.2%) developed mild to moderate exocrine pancreatic insufficiency with 100μg/g<FE-1<200μg/g and 7 patients (6.2%) were diagnosed with severe exocrine pancreatic insufficiency with FE-1<100μg/g. The morbidity of DM and IGT in patients with pancreatic necrosis was significant higher than that in the non-pancreatic necrosis group (X  = 13.442,P = 0.001). The multiple logistic regression analysis showed that extent of pancreatic necrosis<30% (P = 0.012, OR = 0.061) were the protective factors of endocrine pancreatic insufficiency. HOMA-IR (P = 0.002, OR = 6.626), Wall-off necrosis (WON) (P = 0.013, OR = 184.772) were the risk factors.

Conclusion: The integrated morbidity of DM and IGT after AP was 59.25%, which was higher than exocrine pancreatic insufficiency. 6.2% and 29.2% of patients developed severe and mild to moderate exocrine pancreatic insufficiency, respectively. The extent of pancreatic necrosis>50%, WON and insulin resistance were the independent risk factors of new onset diabetes after AP.

Citing Articles

Exploring the pathogenesis, biomarkers, and potential drugs for type 2 diabetes mellitus and acute pancreatitis through a comprehensive bioinformatic analysis.

Zhong L, Yang X, Shang Y, Yang Y, Li J, Liu S Front Endocrinol (Lausanne). 2024; 15:1405726.

PMID: 39634181 PMC: 11614670. DOI: 10.3389/fendo.2024.1405726.


Symptoms, burden, and unmet needs of patients living with exocrine pancreatic insufficiency: a narrative review of the patient experience.

Barkin J, Delk T, Powell V BMC Gastroenterol. 2024; 24(1):101.

PMID: 38481137 PMC: 10938721. DOI: 10.1186/s12876-024-03188-w.


Risk factors for diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis.

Zahariev O, Bunduc S, Kovacs A, Demeter D, Havelda L, Budai B Front Med (Lausanne). 2024; 10:1257222.

PMID: 38264039 PMC: 10803425. DOI: 10.3389/fmed.2023.1257222.


Extracellular Vesicle Content Changes Induced by Melatonin Promote Functional Recovery of Pancreatic Beta Cells in Acute Pancreatitis.

Shao Y, Wu W, Fan F, Liu H, Ming Y, Liao W J Inflamm Res. 2024; 16:6397-6413.

PMID: 38161354 PMC: 10757806. DOI: 10.2147/JIR.S430916.


Diabetes mellitus as a consequence of acute severe pancreatitis: Unraveling the mystery.

Manrai M, Singh A, Birda C, Shah J, Dutta A, Bhadada S World J Diabetes. 2023; 14(8):1212-1225.

PMID: 37664472 PMC: 10473947. DOI: 10.4239/wjd.v14.i8.1212.


References
1.
Dominici R, Franzini C . Fecal elastase-1 as a test for pancreatic function: a review. Clin Chem Lab Med. 2002; 40(4):325-32. DOI: 10.1515/CCLM.2002.051. View

2.
Stram M, Liu S, Singhi A . Chronic Pancreatitis. Surg Pathol Clin. 2016; 9(4):643-659. DOI: 10.1016/j.path.2016.05.008. View

3.
Riveline J, Boudou P, Blondeau B, Gautier J . Glucagon-secretion inhibition using somatostatin: An old hormone for the treatment of diabetes-associated pancreatectomy. Diabetes Metab. 2016; 43(3):269-271. DOI: 10.1016/j.diabet.2016.08.002. View

4.
Das S, Singh P, Phillips A, Murphy R, Windsor J, Petrov M . Newly diagnosed diabetes mellitus after acute pancreatitis: a systematic review and meta-analysis. Gut. 2013; 63(5):818-31. DOI: 10.1136/gutjnl-2013-305062. View

5.
Halter J . Diabetes mellitus in an aging population: the challenge ahead. J Gerontol A Biol Sci Med Sci. 2012; 67(12):1297-9. DOI: 10.1093/gerona/gls201. View